Is there aggravating effect of hyperbaric oxygentherapy on diabetic retinopathy and macular edema? Hiperbarik Oksijen Tedavisi Sonrası Diyabetik Retinopatide İlerleme ve Maküla Ödeminde Artış Olabilir mi?
Retina-Vitreus, cilt.28, sa.1, ss.88-93, 2020 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 1
- Basım Tarihi: 2020
- Dergi Adı: Retina-Vitreus
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.88-93
- Anahtar Kelimeler: Diabetic macular edema, Diabetic retinopathy, Hyperbaric oxygen therapy
- Kırklareli Üniversitesi Adresli: Evet
Özet
A 54-years-old diabetic patient was referred to our clinic for fundus examination. The best corrected visual acuity (BCVA) with Snellen chart was 0.3 and 0.5 in the right and left eyes, respectively. In the fundus examination, moderate non-proliferative diabetic retinopathy (DR) signs and diabetic macular edema (DME) were detected in both eyes. FFA imaging was planned. OCT showed increased macular thickness (CMT) in both eyes, DME and serous macular detachment. Three monthly intravitreal anti-VEGF injection was recommended for both eyes. However, we were unable to treat the patient due to presence of diabetic foot; thus, the patient underwent hyperbaric oxygen therapy (HBOT) over a month. However, the patient presented with accelerated decrease in vision in both eyes 10 day after completion of HBOT. The BCVA was found as 0.1 and 0.05 in the right and left eyes, respectively. In addition, it was found that there was worsening in DME, serous macular detachment in both eyes with optic disc neovascularization (NVD) in the left eye. The disease progression may be due to poor diabetes regulation in the patient and inability to receive intravitreal treatment. However, the fact that there was no loss in visual acuity during HBOT but occurred on day after the completion of HBOT and that NVD was developed in this period should be questioned. We think that the sudden drop in oxygen saturation after the end of HBOT may have contributed to this situation. We believe that this condition should be addressed in all patients with elevated VEGF levels, such as DR.